Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education

Front Page



UK Politics







Talking Point

In Depth

On Air

Low Graphics

Tuesday, October 12, 1999 Published at 02:26 GMT 03:26 UK


Virus breakthrough offers hepatitis C hope

Injecting with dirty needles is the primary cause of new infections

A drug that stops viruses spreading through the body could eventually produce more effective treatment against hard-to-treat hepatitis C.

British experts think that the drug, N-nonyl-BNJ, could be used in combination with other therapies to increase the number of people who can be cured.

So far the treatment has been used with some success against a similar virus to the hepatitis C virus (HCV), as HCV cannot be grown artificially for lab experiments.

But Dr Timothy Block, from the Thomas Jefferson University in Philadelphia, who has developed the drug, believes it could eventually work against both HCV and Hepatitis B.

As many as one in 100 people in the UK are thought to carry HCV, which can damage the liver so badly that a transplant is needed to prevent death.

Sugary secret

Viruses spread by multiplying inside cells, then breaking through the cell wall to spread elsewhere.

To slip through the cell membrane, they develop a sugary coat, and the new drug works by inhibiting this process.

So far it has only been successful against a cow virus, as HCV cannot be grown artificially in a laboratory.

Dr Block said: "This is the first drug since alpha-interferon to my knowledge for which there is published experimental evidence against HCV."

However, a British expert said there was still a long way to go before the treatment would be in routine use.

Dr Graham Foster, senior lecturer in hepatology at St Mary's Hospital, Paddington, said it represented a "promising development", and could probably eventually be used in combination with other drugs.

He said: "It may stop the viruses getting out of the cell, but if they continue to accumulate, the cell may burst eventually anyway.

"The drug has never actually been used on patients to any great degree."

Costly treatment

He said that HCV was "public enemy number one" in the UK, with an estimated one in 100 people infected.

"The problem is, there are so few treatments."

About 30% of long-term carriers of the virus will develop cirrhosis, or liver cancer.

The current treatment, interferon, when combined with another drug, cures about 40% of those carrying the virus.

But a 12-month course costs £10,000, and involves unpleasant side-effects.

The principal cause of new infections is sharing needles for intravenous drug use, and the number of people presenting with symptoms is projected to rise sharply over the next decade to reflect a rise in the number of needle-users two decades ago.

Advanced options | Search tips

Back to top | BBC News Home | BBC Homepage | ©

Health Contents

Background Briefings
Medical notes

Relevant Stories

29 Jul 99†|†Health
Hepatitis C tests win approval

20 Jul 99†|†Health
Hepatitis outbreak sparks clampdown call

20 May 99†|†Health
Drug users fuel hepatitis boom

Internet Links

British Liver Trust


The BBC is not responsible for the content of external internet sites.

In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99